Compare · BDX vs MHUA
BDX vs MHUA
Side-by-side comparison of Becton Dickinson and Company (BDX) and Meihua International Medical Technologies Co. Ltd. (MHUA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and MHUA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX carries a market cap of $41.33B.
- Over the past year, BDX is down 12.6% and MHUA is down 81.8% - BDX leads by 69.2 points.
- BDX has hit the wire 10 times in the past 4 weeks while MHUA has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 0 for MHUA).
- Company
- Becton Dickinson and Company
- Meihua International Medical Technologies Co. Ltd.
- Price
- $150.71+0.38%
- $7.61-45.80%
- Market cap
- $41.33B
- -
- 1M return
- +0.87%
- -65.53%
- 1Y return
- -12.62%
- -81.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co., Ltd. engages in the manufacture and marketing of medical consumables in the People's Republic of China. It offers class I, II, and III disposable medical devices. The company's products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles. It also distributes disposable medical devices sourced from other manufacturers to customers in China. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest MHUA
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- Meihua International Medical Technologies Co., Ltd. Received Nasdaq Delisting Notice
- Meihua International Announces 1-For-100 Reverse Share Split
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 424B3 filed by Meihua International Medical Technologies Co. Ltd.